Tumor-associated antigens - Immune Biology of Allogeneic Hematopoietic Stem Cell Transplantation - page 157

antigen presentation machinery of APCs [99,100] . It is therefore conceiv-
able that treating patients with drugs that have similar effects on antigen
presentation by target cells could sensitize malignant cells to killing by a
primed immune system.
Conclusion
Targeting TAAs is an attractive immunotherapeutic option for the treatment
of hematological malignancies. TAAs that are exclusively expressed by the
tumor cells provide the ideal immunotherapeutic target, although there is a
paucity of such antigens that are immunogenic. However, the distinct aber-
rant expression of unmutated self-antigens by malignant cells has provided
a number of TAAs that have been targeted successfully. Finding cost-effec-
tive and practical approaches to elicit potent and reproducible immune
responses following TAA-targeting immunotherapies, with limited off-tar-
get toxicities, is a major undertaking. Only after these goals are achieved,
will TAA-targeting of immunotherapies become part of the standard of care
in therapeutic approaches to treat hematological malignancies.
159
References
[1] Alatrash G, Ono Y, Sergeeva A, Sukhumalchandra P, Zhang M, St John LS, et al. The
role of antigen cross-presentation from leukemia blasts on immunity to the leukemia-
associated antigen PR1. J Immunother 2012;35:309-20.
[2] Rock KL, York IA, Goldberg AL. Post-proteasomal antigen processing for major histo-
compatibility complex class I presentation. Nat Immunol 2004;5:670-7.
[3] Levitskaya J, Sharipo A, Leonchiks A, Ciechanover A, Masucci MG. Inhibition of
ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain
of the Epstein-Barr virus nuclear antigen 1. Proc Natl Acad Sci USA 1997;94:
12616-21.
[4] Kageshita T, Hirai S, Ono T, Hicklin DJ, Ferrone S. Down-regulation of HLA class I
antigen-processing molecules in malignant melanoma: association with disease
progression. AmJ Pathol 1999;154:745-54.
[5] Landmeier S, Altvater B, Pscherer S, Juergens H, Varnholt L, Hansmeier A, et al. Acti-
vated human gammadelta T cells as stimulators of specific CD8 + T-cell responses to
subdominant Epstein-Barr virus epitopes: potential for immunotherapy of cancer. J
Immunother 2009;32:310-21.
[6] Molldrem J, et al. Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes
specific for a peptide derived from proteinase 3 preferentially lyse human myeloid
leukemia cells. Blood 1996;88:2450-7.
[7] Molldrem J, Dermime S, Parker K, Jiang YZ, Mavroudis D, Hensel N, et al. Evidence that
specific T lymphocytes may participate in the elimination of chronic myelogenous
leukemia. Nat Med 2000;6:1018-23.
[8] Qazilbash MH, Thall PF, Wang X, Wieder E, Rios R, Kant S, et al. PR1 peptide vac-
cination for patients with myeloid leukemias. ASCO Annual Meeting Proceedings
2007;25:7017.
[9] Rezvani K, Yong AS, Mielke S, Savani BN, Musse L, Superata J, et al. Leukemia-associat-
ed antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccina-
tion in patients with myeloid malignancies. Blood 2008;111:236-42.
[10] Sergeeva A, Alatrash G, He H, Ruisaard K, Lu S, Wygant J, et al. An anti-PR1/HLA-A2 T-
cell receptor-like antibody mediates complement-dependent cytotoxicity against acute
myeloid leukemia progenitor cells. Blood 2011;117:4262-72.
[11] Miwa H, Beran M, Saunders GF. Expression of the Wilms' tumor gene (WT1) in human
leukemias. Leukemia 1992;6:405-9.
[12] Englert C, Hou X, Maheswaran S, Bennett P, Ngwu C, Re GG, et al. WT1 suppresses
synthesis of the epidermal growth factor receptor and induces apoptosis. EMBO J
1995;14:4662-75.
[13] Oka Y, Udaka K, Tsuboi A, Elisseeva OA, Ogawa H, Aozasa K, et al. Cancer immunother-
apy targeting Wilms' tumor gene WT1 product. J Immunol 2000;164:1873-80.